The estimated Net Worth of Tomer Kariv is at least $167 Thousand dollars as of 13 May 2021. Mr. Kariv owns over 5,925,925 units of Eloxx Pharmaceuticals Inc stock worth over $370 and over the last 7 years he sold ELOX stock worth over $0. In addition, he makes $167,100 as Independent Chairman of the Board at Eloxx Pharmaceuticals Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Kariv ELOX stock SEC Form 4 insiders trading
Tomer has made over 7 trades of the Eloxx Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 5,925,925 units of ELOX stock worth $7,999,999 on 13 May 2021.
The largest trade he's ever made was buying 5,925,925 units of Eloxx Pharmaceuticals Inc stock on 13 May 2021 worth over $7,999,999. On average, Tomer trades about 398,845 units every 52 days since 2018. As of 13 May 2021 he still owns at least 616,592 units of Eloxx Pharmaceuticals Inc stock.
You can see the complete history of Mr. Kariv stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Tomer Kariv biography
Tomer Kariv J.D. serves as Independent Chairman of the Board of the Company. Previously served as a member of the Eloxx Limited Board since October 2016. For the past 14 years Mr. Kariv has been the Chief Executive Officer and Co-Founder of The Pontifax Group, which established five funds with over $600 million under management and invested in over 40 portfolio companies. Mr. Kariv also serves on the board of directors of many of The Pontifax Group’s portfolio companies including: V-Wave Ltd., EyeYon Medical Ltd., Cathworks Ltd., Raziel Therapeutics Ltd., VBI Vaccines Inc., LogicBio, and 89Bio Ltd. He previously served as a Director of Medical Compression Systems Ltd., Insuline Medical Ltd., Headsense Medical Ltd., Macrocure Ltd., Avraham Pharmaceuticals, Arno Therapeutics, Stimatix Ltd., Applied Immune Technologies, Allium Ltd., Tucos, Inc., Therapix Biosciences Ltd., Otic Pharma Ltd., Observer in Entera Ltd., Nutrinia Ltd., Check-Cap Ltd., and CollPlant Holdings Ltd.
What is the salary of Tomer Kariv?
As the Independent Chairman of the Board of Eloxx Pharmaceuticals Inc, the total compensation of Tomer Kariv at Eloxx Pharmaceuticals Inc is $167,100. There are 6 executives at Eloxx Pharmaceuticals Inc getting paid more, with Gregory Williams having the highest compensation of $2,690,850.
How old is Tomer Kariv?
Tomer Kariv is 59, he's been the Independent Chairman of the Board of Eloxx Pharmaceuticals Inc since 2020. There are 6 older and 5 younger executives at Eloxx Pharmaceuticals Inc. The oldest executive at Eloxx Pharmaceuticals Inc is Zafrira Avnur, 68, who is the Independent Director.
What's Tomer Kariv's mailing address?
Tomer's mailing address filed with the SEC is C/O KEROS THERAPEUTICS, INC., 1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421.
Insiders trading at Eloxx Pharmaceuticals Inc
Over the last 7 years, insiders at Eloxx Pharmaceuticals Inc have traded over $0 worth of Eloxx Pharmaceuticals Inc stock and bought 22,391,804 units worth $47,296,070 . The most active insiders traders include Ran Nussbaum, Tomer Kariv, and Steven D Rubin. On average, Eloxx Pharmaceuticals Inc executives and independent directors trade stock every 26 days with the average trade being worth of $275. The most recent stock trade was executed by Alan Edmund Walts on 1 December 2021, trading 37,695 units of ELOX stock currently worth $23.
What does Eloxx Pharmaceuticals Inc do?
eloxx pharmaceuticals, inc. is a clinical-stage biopharmaceutical company developing novel rna-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. premature stop codons are point mutations that disrupt protein synthesis from messenger rna. as a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. these premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. read-through therapeutic development is focused on extending mrna half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. eloxx’s lead product candidate, elx-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. elx-02 is in the early stages of clin
What does Eloxx Pharmaceuticals Inc's logo look like?
Complete history of Mr. Kariv stock trades at VBI Vaccines, Eloxx Pharmaceuticals Inc, ContextLogic Inc, and Keros Therapeutics
Eloxx Pharmaceuticals Inc executives and stock owners
Eloxx Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Gregory Williams,
Chief Executive Officer, Director -
Martijn Kleijwegt,
Independent Director -
Steven Rubin,
Independent Director -
Ran Nussbaum,
Independent Director -
Zafrira Avnur,
Independent Director -
Jasbir Seehra,
Independent Director -
Gadi Veinrib,
Independent Director -
Tomer Kariv,
Independent Chairman of the Board -
Silvia Noiman,
Director -
Stephen MacDonald,
Principal Accounting Officer, Vice President - Finance and Accounting, Treasurer -
Neil Belloff,
Chief Operating Officer, General Counsel, Corporate Secretary -
Matthew Goddeeris Ph.D.,
VP of Research -
Dr. Ali Hariri M.D.,
Chief Medical Officer -
Dr. Vijay Modur MBBS, Ph.D.,
Head of R&D -
Rose Villandry,
VP of HR -
Barbara Ryan,
Investor Relations Officer -
Daniel E. Geffken M.B.A., MBA,
Interim CFO, Principal Financial Officer & Principal Accounting Officer -
Sumit Aggarwal M.B.A.,
Pres, CEO & Director -
David P. Snow,
-
Robert Ward,
-
Management 4 G.P. (2015) Lt...,
-
Management 4 G.P. (2015) Lt...,
-
Management Iii G.P. (2011) ...,
-
Gilad Shabtai,
10% owner -
Management 4 G.P. (2015) Lt...,
-
Gregory L Weaver,
-
Sumit Aggarwal,
PRESIDENT AND CEO -
Vijay Modur,
HEAD OF R&D -
Rajesh B Parekh,
Director -
Daniel E. Geffken,
INTERIM CFO -
Lindsay Androski,
Director -
Alan Edmund Walts,
Director